Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study

Trial Profile

Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2016

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Graft-versus-host disease; Immunodeficiency disorders; Leukaemia
  • Focus Pharmacodynamics
  • Acronyms PARACHUTE
  • Most Recent Events

    • 10 Mar 2015 New source identified and integrated as Netherlands Trial Register (NTR4960).
    • 24 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top